Gubra A/S (PI3.F)
Frankfurt · EUR · Healthcare · Biotechnology
€38.60 (-0.57%) as of
Key statistics
- Market cap
- 633.77M
- EPS (TTM)
- -1.51
- Dividend yield
- 0.00%
- 52-week range
- 37.18 – 73.15
- Beta
- 0.45
- Revenue (TTM)
- 271.02M
- Profit margin
- -67.25%
- Volume
- 75.00
About Gubra A/S
Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry; and various services in vivo pharmacology, biomarker assays, bioinformatics, next gen sequencing, bioinformatics, and 2D and 3D histology with artificial intelligence pathology. It also has a portfolio strategy of potential drug candidates in the form of upfront payments, research payments, milestone payments, and royalties; and investments targeting as sets promoting the green transition. The company has partnership and collaboration with Boehringer Ingelheim for the treatment of obesity; Camurus' FluidCrystal technology to develop a therapy for hypoparathyroidism; Amylyx Pharmaceuticals to develop a GLP-1 receptor antagonist for post-bariatric hypoglycemia and other rare diseases. Gubra A/S was incorporated in 2008 and is headquartered in Horsholm, Denmark.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Horsholm, Denmark
- Employees
- 330
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.